Literature DB >> 33737188

Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis-New insight and futuristic vision.

Xiao Lin Huang1, Muhammad Imran Khan2, Jing Wang3, Rizwan Ali4, Syed Wajahat Ali4, Qurat-Ul-Ain Zahra4, Ahsan Kazmi5, Arbelo Lolai1, Yu Lin Huang1, Alamdar Hussain6, Muhammad Bilal7, Fenfen Li8, Bensheng Qiu9.   

Abstract

In the past two decades, significant progress has been made in the past two decades towards the understanding of the basic mechanisms underlying cancer growth and angiogenesis. In this context, receptor tyrosine kinases (RTKs) play a pivotal role in cell proliferation, differentiation, growth, motility, invasion, and angiogenesis, all of which contribute to tumor growth and progression. Mutations in RTKs lead to abnormal signal transductions in several pathways such as Ras-Raf, MEK-MAPK, PI3K-AKT and mTOR pathways, affecting a wide range of biological functions including cell proliferation, survival, migration and vascular permeability. Increasing evidence demonstrates that multiple kinases are involved in angiogenesis including RTKs such as vascular endothelial growth factor, platelet derived growth factor, epidermal growth factor, insulin-like growth factor-1, macrophage colony-stimulating factor, nerve growth factor, fibroblast growth factor, Hepatocyte Growth factor, Tie 1 & 2, Tek, Flt-3, Flt-4 and Eph receptors. Overactivation of RTKs and its downstream regulation is implicated in tumor initiation and angiogenesis, representing one of the hallmarks of cancer. This review discusses the role of RTKs, PI3K, and mTOR, their involvement, and their implication in pro-oncogenic cellular processes and angiogenesis with effective approaches and newly approved drugs to inhibit their unrestrained action.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Cancer therapies; Receptor tyrosine kinase signaling; Tumor growth

Year:  2021        PMID: 33737188     DOI: 10.1016/j.ijbiomac.2021.03.075

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  7 in total

Review 1.  Role of gene regulation and inter species interaction as a key factor in gut microbiota adaptation.

Authors:  Shuang Gao; Muhammad Imran Khan; Fadia Kalsoom; Zhen Liu; Yanxin Chen; Zhengli Chen
Journal:  Arch Microbiol       Date:  2022-05-20       Impact factor: 2.552

2.  A Positive Feedback Loop between Inactive VHL-Triggered Histone Lactylation and PDGFRβ Signaling Drives Clear Cell Renal Cell Carcinoma Progression.

Authors:  Jiefeng Yang; Li Luo; Chongyu Zhao; Xiyuan Li; Zimo Wang; Ziwei Zeng; Xin Yang; Xiaobin Zheng; Haiqing Jie; Liang Kang; Shujuan Li; Shuang Liu; Chi Zhou; Huashan Liu
Journal:  Int J Biol Sci       Date:  2022-05-13       Impact factor: 10.750

3.  Tyrosine Phosphorylation Profiling Revealed the Signaling Network Characteristics of CAMKK2 in Gastric Adenocarcinoma.

Authors:  Mohd Altaf Najar; Mohammad Arefian; David Sidransky; Harsha Gowda; T S Keshava Prasad; Prashant Kumar Modi; Aditi Chatterjee
Journal:  Front Genet       Date:  2022-05-13       Impact factor: 4.772

4.  In Vitro Angiogenesis Inhibition and Endothelial Cell Growth and Morphology.

Authors:  Arlinda Ljoki; Tanzila Aslam; Tina Friis; Ragnhild G Ohm; Gunnar Houen
Journal:  Int J Mol Sci       Date:  2022-04-12       Impact factor: 6.208

Review 5.  Nanotechnology-based immunotherapies to combat cancer metastasis.

Authors:  Yuping Zhao; Muhammad Bilal; Maimoona Qindeel; Muhammad Imran Khan; Kuldeep Dhama; Hafiz M N Iqbal
Journal:  Mol Biol Rep       Date:  2021-08-23       Impact factor: 2.316

6.  microRNA-301a-3p is a potential biomarker in venous ulcers vein and gets involved in endothelial cell dysfunction.

Authors:  Ying Wang; Jingchen Du; Yu Liu; Shuhui Yang; Qingshan Wang
Journal:  Bioengineered       Date:  2022-06       Impact factor: 6.832

Review 7.  An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors.

Authors:  Yingchao Sun; Lei Yue; Pengfu Xu; Weiling Hu
Journal:  Front Oncol       Date:  2022-08-31       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.